Effect of Physical Activity on the Development and the Resolution of Nonalcoholic Fatty Liver in Relation to Body Mass Index

Hyo-In Choi  
Sungkyunkwan University School of Medicine

Mi Yeon Lee  
Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine

Hyunah Kim  
Sungkyunkwan University School of Medicine

Byeong Kil Oh  
Sungkyunkwan University School of Medicine

Seung Jae Lee  
Sungkyunkwan University School of Medicine

Jeong Gyu Kang  
Total Healthcare Center, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine

Sung Ho Lee  
Sungkyunkwan University School of Medicine

Byung Jin Kim  
Sungkyunkwan University School of Medicine

Bum Soo Kim  
Sungkyunkwan University School of Medicine

Jin Ho Kang  
Sungkyunkwan University School of Medicine

Jong-Young Lee  (jyleeheart@naver.com)  
Sungkyunkwan University School of Medicine

Ki-Chul Sung  
Sungkyunkwan University School of Medicine

Research Article

Keywords: Physical activity, fatty liver, body-mass index, prevention, epidemiology

Posted Date: December 29th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-1136331/v1
Abstract

BACKGROUND

Data on whether physical activity (PA) levels are related to nonalcoholic fatty liver disease (NAFLD) when considering body mass index (BMI) are scarce. We assessed whether PA affects the development or resolution of NAFLD in conjunction with BMI changes.

METHODS

Overall, 130,144 participants who underwent health screening during 2011-2016 were enrolled. According to the PA level in the Korean version of the validated International PA Questionnaire Short Form, participants were classified into the inactive, active, and health-enhancing PA (HEPA) groups.

RESULTS

In participants with increased BMI, the hazard ratio (HR) and 95% confidence interval after multivariable Cox hazard model for incident NAFLD was 0.97 (0.94-1.01) in the active group and 0.94 (0.89-0.99) in the HEPA group, whereas that for NAFLD resolution was 1.03 (0.92-1.16) and 1.04 (0.88-1.23) (reference: inactive group). With increased BMI, high PA affected only new incident NAFLD. PA enhancement or maintenance of sufficient PA prevented new incident NAFLD. In participants with decreased BMI, the HRs were 0.98 (0.90-1.07) and 0.88 (0.78-0.99) for incident NAFLD and 1.07 (0.98-1.17) and 1.33 (1.18-1.49) for NAFLD resolution in the active and HEPA groups, respectively. With decreased BMI, high PA reduced incident NAFLD and increased NAFLD resolution. Maintenance of sufficient PA led to a considerable resolution of NAFLD.

CONCLUSION

In this large longitudinal study, PA prevented incident NAFLD regardless of BMI changes. For NAFLD resolution, sufficient PA was essential along with BMI decrease. Maintaining sufficient PA or increasing the PA level is crucial for NAFLD prevention or resolution.

Introduction

Nonalcoholic fatty liver disease (NAFLD) is a multisystem disease characterized by fat accumulation in the liver that is not triggered by excessive drinking. Lifestyle and dietary habits have resulted in a considerable increase in the prevalence of NAFLD along with obesity and diabetes. The prevalence of NAFLD as assessed by liver ultrasonography (US) has been reported to range from 17–46%, depending
on the investigated population. Individuals with NAFLD had a higher overall mortality rate than matched control populations, with cardiovascular disease being the most common cause of death.

Lifestyle modifications such as diet, exercise, and weight loss have been recommended to improve NAFLD. Most individuals with NAFLD have inadequate physical activity (PA), which is associated with a higher NAFLD risk. We previously reported that moderate exercise was associated with the greatest benefit in terms of preventing NAFLD or improving existing NAFLD, regardless of body mass index (BMI) changes, over a 5-yr follow-up period. However, the impact of PA on the development and resolution of NAFLD in different BMI change groups (increasing or decreasing) could not be determined. Increased PA or exercise frequently results in weight loss, but some individuals gain weight. To the best of our knowledge, no large-scale study has examined the impact of PA on NAFLD in relation to changes in BMI. So, this study aimed to determine whether PA levels are associated with the resolution of existing NAFLD or a reduced risk of incident NAFLD development in different BMI change groups using a large cohort data of Korean adults who underwent regular health examinations.

**Materials And Methods**

**STUDY POPULATION**

Our study population (n=228,589) consisted of individuals who participated at least twice in a comprehensive health screening program that included assessment of PA using the validated Korean version of the International PA Questionnaire Short Form (IPAQ-SF) at Kangbuk Samsung Hospital, Seoul, Korea, between 2011 and 2016. The aim of the health screening program was to promote health by detecting chronic diseases and associated risk factors. To examine the association of PA with the incidence or resolution of NAFLD independent of BMI changes, we excluded participants with age < 20 (n=46), missing data on BMI (n=216 at baseline/n=876 at follow-up), waist circumference (n=38,542 at baseline/n= 1,116 at follow-up), fatty liver (n=654 at baseline/n=1,044 at follow-up), and cancer history (n=5,203). Participants were also excluded if they tested positive for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody (n=8,090) and if they had a daily alcohol consumption of >20 g (men) or >10 g (women) (n=49,428). Individuals who were taking medications for hypertension, diabetes, or dyslipidemia were also excluded (n=15,122) to eliminate interference from these factors. Some participants met multiple exclusion criteria, and a total of 130,144 participants were finally included in this study (mean age, 37.16 yr; 52.8% men). The median follow-up duration was 3.03 yr (368,555 person-year). The Kangbuk Samsung Hospital Institutional Review Board approved this study and waived the requirement for informed consent because we used only de-identified data obtained as part of the health screening examinations (IRB No. 2018-05-050).

**DATA COLLECTION AND MEASUREMENTS**

Information about medical and family history, medication use, lifestyle factors, and education level was obtained through a self-administered questionnaire. Blood pressure and anthropometrical parameters
were measured by trained staff during the health examinations. Body weight and height were measured, with the participants in light clothing and without shoes, to the nearest 0.1 kg and 0.1 cm, respectively. BMI was calculated by dividing the weight in kilograms by the height in meters squared. The average amount of alcohol consumed per day was estimated using the frequency and amount of alcohol consumed per drinking day. The PA level was assessed using the validated Korean version of the IPAQ-SF. The IPAQ-SF provides separate scores for walking, moderate-intensity activity, and vigorous-intensity activity, as well as a combined total score to describe the overall level of activity. Additionally, the volume of activity was computed by weighting each type of activity according to its energy requirements defined in metabolic equivalents (MET) to yield a score in MET/min. The participants were categorized according to PA level into the inactive, active, and health-enhancing PA (HEPA) groups. HEPA was defined as any of the following criteria were met: (i) vigorous-intensity activity ≥3 days/wk accumulating ≥1500 MET min/wk or (ii) 7 days of any combination of walking, moderate-intensity activity, or vigorous-intensity activity achieving at least 3000 MET min/wk. Participants were characterized as active if any of the following criteria were met: (i) ≥3 days of vigorous-intensity activity for ≥20 min/day, (ii) ≥5 days of moderate-intensity activity or walking for ≥30 min/day, or (iii) ≥5 days of any combination of walking and moderate- or vigorous-intensity activity achieving ≥600 MET min/wk. Participants were characterized as inactive if they did not meet the criteria for either the active or HEPA categories.

Abdominal US (Logic Q700 MR; GE, Milwaukee, WI, USA) was performed by clinical radiologists using a 3.5-MHz probe at baseline and follow-up for all participants. The following images were obtained: (i) sagittal view of the right lobe of the liver and right kidney, (ii) transverse view of the left lateral segment of the liver and spleen, and (iii) transverse view of the liver for altered echo texture. Fatty infiltration of the liver (NAFLD) was considered present if the echogenicity of the liver was greater than that of the renal cortex, with the diaphragm and intrahepatic vessels appearing normal.

STATISTICAL ANALYSES

Descriptive statistics are used to summarize the characteristics of the participants in separate PA categories. The incidence rate was expressed as the number of cases of incident NAFLD or resolution of NAFLD per 100 person-yr (PY). The adjusted hazard ratio (HR) and 95% CI for incident NAFLD development and NAFLD resolution were estimated using a Cox proportional hazards model. Three regression models were generated for each outcome: model 1 was adjusted for age, sex, center, year of screening examination, smoking status, alcohol intake, and education level; model 2 was adjusted for variables in model 1 plus waist circumference; and model 3 was adjusted for variables in model 2 plus waist circumference changes. We used the inactive group as the reference category. The Kaplan–Meier curves were used to illustrate time-to-event outcomes in each PA group, with the results being compared using the log rank test. Statistical significance was set at p<0.05. Statistical analyses were conducted using Stata (version 16.1; StataCorp LP, College Station, TX, USA).

Results
PA AND NAFLD WITH TEMPORAL CHANGES IN BMI

This cohort study enrolled 130,144 participants (mean age, 37.2 yr; 52.8% men) who underwent comprehensive health screening examinations at Kangbuk Samsung Hospital between 2011 and 2016. A total of 95,959 individuals were identified to have no NAFLD at baseline, of whom 14,066 developed incident NAFLD during the follow-up period. 34,185 participants were identified to have NAFLD at baseline, which resolved in 3,755 individuals during the follow-up period. The baseline characteristics of the participants according to NAFLD status are shown in Supporting Table S1. All traditional cardiovascular and metabolic risk factors (age, male sex, lipid profile, fasting glucose, insulin, homeostatic model assessment of insulin resistance [HOMA-IR], blood pressure, and smoking) were more adversely affected in participants with NAFLD than in those without NAFLD. Table 1 shows the baseline characteristics of the participants categorized according to PA levels. Increasing PA categories were positively associated with age, male sex, BMI, systolic blood pressure, alcohol intake, and glucose levels and better insulin resistance markers (lower insulin level and HOMA-IR score). 87,316 individuals increased their BMI during the follow-up period, while 42,828 individuals maintained or decreased their BMI (Table 2). With respect to temporal BMI changes, participants who had increased BMI during the follow-up period had younger age; lower glucose level, insulin level, BMI, and waist circumference; and better lipid profiles at baseline. Participants with increased BMI had higher HOMA-IR scores than those with decreased BMI despite better other cardiometabolic profiles.
|                                | Inactive (n=64,688) | Active (n=46,325) | HEPA (n=19,131) | P value |
|--------------------------------|---------------------|-------------------|-----------------|---------|
| **Age (years)**                | 36.71±6.50          | 37.25±7.09        | 38.41±8.06      | <0.001  |
| **Male (n, %)**                | 29,550 (45.99)      | 27,950 (60.33)    | 11,002 (57.51)  | <0.001  |
| **Glucose (mg/dL)**            | 92.76±11.45         | 93.37±10.93       | 93.40±10.45     | <0.001  |
| **AST (IU/L)**                 | 20.58±10.44         | 21.32±10.65       | 21.94±12.78     | <0.001  |
| **ALT (IU/L)**                 | 21.62±18.44         | 22.72±18.73       | 21.41±16.48     | <0.001  |
| **GGT (IU/L)**                 | 26.12±28.55         | 27.53±27.85       | 25.45±26.27     | <0.001  |
| **Triglyceride (mg/dL)**       | 85 (61-125)         | 88 (63-129)       | 81 (59-117)     | 0.0001  |
| **HDL-cholesterol (mg/dL)**    | 58.68±14.84         | 57.87±14.70       | 59.84±15.15     | <0.001  |
| **LDL-cholesterol (mg/dL)**    | 117.70±31.42        | 119.89±31.06      | 118.61±30.60    | <0.001  |
| **Insulin (IU/mL)**            | 5.92±3.72           | 5.66±3.55         | 5.18±4.01       | <0.001  |
| **HOMA IR**                    | 1.38±0.98           | 1.33±0.93         | 1.22±1.02       | <0.001  |
| **BMI (kg/m²)**                | 22.66±3.29          | 23.08±3.17        | 23.25±3.05      | <0.001  |
| **Waist (cm)**                 | 80.14±9.48          | 81.27±9.13        | 81.02±8.79      | <0.001  |
| **SBP (mmHg)**                 | 105.75±12.37        | 108.01±12.52      | 108.85±12.79    | <0.001  |
| **DBP (mmHg)**                 | 68.00±9.48          | 69.09±9.49        | 69.02±9.50      | 0.964   |
| **Education**                  |                     |                   |                 | <0.001  |
| ≤High school                   | 8,014 (12.39)       | 3,856 (8.32)      | 3,024 (15.81)   |         |
| ≥College graduate              | 50,350 (77.84)      | 36,438 (78.66)    | 13,684 (71.53)  |         |
| Unknown                        | 6,324 (9.78)        | 6,031 (13.02)     | 2,423 (12.67)   |         |
| **Smoking status (n, %)**      |                     |                   |                 | <0.001  |
| Never/former smoker            | 49,091 (75.89)      | 33,400 (72.10)    | 13,864 (72.47)  |         |
| Current smoker                 | 10,590 (16.37)      | 8,938 (19.29)     | 3,256 (17.02)   |         |
| Unknown                        | 5,007 (7.74)        | 3,987 (8.61)      | 2,011 (10.51)   |         |
| Alcohol (g/day)                | 4 (1-10)            | 5 (2-11)          | 5 (2-11)        | 0.001   |
| **NAFLD**                      | 16,447 (25.43)      | 13,088 (28.25)    | 4,650 (24.31)   | <0.001  |
| Inactive (n=64,688) | Active (n=46,325) | HEPA (n=19,131) | P value |
|---------------------|-------------------|-----------------|---------|

Numbers are mean (standard deviation), median (interquartile range), or percentages.

*Triglyceride was log-transformed for this analysis.

†

Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; HDL-cholesterol, high-density lipoprotein cholesterol; HEPA, health-enhancing physical activity; HOMA-IR, Homeostatic Model Assessment for Insulin Resistance; LDL-cholesterol, low-density lipoprotein cholesterol; NAFLD, non-alcoholic fatty liver disease; SBP, systolic blood pressure.
|                      | BMI Change >0 (n=87,316) | BMI Change ≤0 (n=42,828) | P value |
|----------------------|--------------------------|---------------------------|---------|
| Age (years)          | 36.76±6.74               | 37.95±7.40                | <0.001  |
| Male (n, %)          | 46,007 (52.69)           | 22,695 (52.99)            | 0.307   |
| Glucose (mg/dL)      | 92.49±10.18              | 94.26±12.77               | <0.001  |
| AST (IU/L)           | 20.70±10.22              | 21.76±12.13               | <0.001  |
| ALT (IU/L)           | 21.19±17.37              | 23.60±19.90               | <0.001  |
| GGT (IU/L)           | 25.50±26.31              | 28.61±31.02               | <0.001  |
| Triglyceride (mg/dL)*| 83 (60,120)              | 92 (65,137)               | <0.001  |
| HDL-cholesterol (mg/dL) | 59.15±14.82           | 57.35±14.83               | <0.001  |
| LDL-cholesterol (mg/dL) | 117.26±30.83          | 121.37±31.74              | <0.001  |
| Insulin (IU/mL)      | 5.52±3.63                | 6.11±3.84                 | <0.001  |
| HOMA IR              | 1.28±0.92                | 1.16±1.06                 | <0.001  |
| BMI (kg/m²)          | 22.64±3.18               | 23.42±3.25                | <0.001  |
| Waist (cm)           | 79.98±9.18               | 82.08±9.29                | <0.001  |
| SBP (mmHg)           | 106.59±12.39             | 107.87±12.97              | <0.001  |
| DBP (mmHg)           | 68.27±9.31               | 69.08±9.85                | <0.001  |
| Education            |                          |                           |         |
| ≤High school         | 10,069 (11.53)           | 4,825 (11.27)             |         |
| ≥College graduate    | 67,534 (77.34)           | 32,938 (76.91)            |         |
| Unknown              | 14,778 (11.36)           | 5,065 (11.83)             |         |
| Smoking status (n, %)|                          |                           | <0.001  |
| Never/former smoker  | 64,505 (73.88)           | 31,850 (74.37)            |         |
| Current smoker       | 15,585 (17.85)           | 7,199 (16.81)             |         |
| Unknown              | 7,226 (8.28)             | 3,779 (8.82)              |         |
| Alcohol (g/day)      | 4 (2, 10)                | 4 (1, 10)                 | 0.496   |
| NAFLD                | 20,619 (23.61)           | 13,566 (31.68)            | <0.001  |
| BMI Change >0 (n=87,316) | BMI Change ≤0 (n=42,828) | P value |
|---------------------------|---------------------------|---------|
| Numbers are mean (standard deviation), median (interquartile range), or percentages. |

*Triglyceride was log-transformed for this analysis.

Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; HDL-cholesterol, high-density lipoprotein cholesterol; HEPA, health-enhancing physical activity; HOMA-IR, Homeostatic Model Assessment for Insulin Resistance; LDL-cholesterol, low-density lipoprotein cholesterol; NAFLD, non-alcoholic fatty liver disease; SBP, systolic blood pressure.

The HRs for NAFLD resolution or incident NAFLD development according to the PA category in different BMI change groups are shown in Table 3 (increasing BMI group) and Table 4 (decreasing BMI group). In participants with increased BMI during the follow-up period (Table 3), HEPA was associated with a lower risk of incident NAFLD (HR [95% CI], 0.94 [0.89-0.99], inactive group as reference). However, in increasing BMI group, active PA and HEPA did not show an association with increased resolution of NAFLD (HR [95% CI], 1.03 [0.92-1.16] for active and 1.04 [0.88-1.23] for HEPA group, respectively). In participants with decreased BMI (Table 4), HEPA was associated with a higher chance of NAFLD resolution and a lower risk of incident NAFLD. The multivariable-adjusted HR (95% CI) was 1.33 (1.18-1.49) for resolution of NAFLD and 0.88 (0.78-0.99) for incident NAFLD in HEPA when compared to inactive group as reference. Figure 1 represents event free survival curves for resolution and development of NAFLD in each BMI change groups. Supporting Fig. S1 shows spline curves displaying the risk of (A) resolution and (B) incidence of NAFLD in overall and the three activity groups (Model 3).
Table 3
HR of Resolution and Incident NAFLD According to PA category in BMI Change >0 Group

| Resolution of NAFLD | Person-years | Events (No.) | Event rate (per 100,000 person-years) | Age- and sex-adjusted HR (95% CI) | Multivariable-adjusted HR (95% CI) |
|---------------------|--------------|--------------|---------------------------------------|----------------------------------|-----------------------------------|
|                     |              |              |                                       | Model 1                          | Model 2                           | Model 3                           |
| Inactive            | 27,572.3     | 644          | 2.3                                   | 1.00 (1.00)                      | 1.00 (1.00)                       | 1.00 (1.00)                       |
| Active              | 24,221.6     | 507          | 2.1                                   | 1.00 (1.00-1.12)                 | 1.04 (0.92-1.17)                  | 1.02 (0.91-1.15)                  |
| HEPA                | 8,493.0      | 185          | 2.2                                   | 0.96 (0.82-1.14)                 | 1.01 (0.86-1.19)                  | 1.01 (0.85-1.19)                  |

| Incident NAFLD     |              |              |                                       | Model 1                          | Model 2                           | Model 3                           |
|---------------------|--------------|--------------|---------------------------------------|----------------------------------|-----------------------------------|-----------------------------------|
| Inactive            | 94,031.3     | 5,216        | 5.5                                   | 1.00 (1.00)                      | 1.00 (1.00)                       | 1.00 (1.00)                       |
| Active              | 69,460.8     | 4,455        | 6.4                                   | 0.95 (1.91-0.99)                 | 0.98 (0.94-1.02)                  | 0.98 (0.94-1.02)                  |
| HEPA                | 30,079.8     | 1,983        | 6.6                                   | 0.97 (0.92-1.02)                 | 0.99 (0.94-1.05)                  | 0.99 (0.94-1.04)                  |

Model 1: adjustment for age, sex, center, year of screening exam, smoking status, alcohol intake, education level

Model 2: model 1 adjustments plus adjustment for waist circumference

Model 3: model 2 adjustments plus adjustment for waist circumference changes

The reference group was inactive group.

Abbreviations: BMI, body mass index; CI, confidence interval; HEPA, health-enhancing physical activity; HR, hazard ratio; NAFLD, non-alcoholic fatty liver disease; PA, physical activity.
|                      | Person-years | Events (No.) | Event rate (per 100,000 person-years) | Age- and sex-adjusted HR (95% CI) | Multivariable-adjusted HR (95% CI) |
|----------------------|--------------|--------------|--------------------------------------|-----------------------------------|-----------------------------------|
|                      |             |              |                                      | Model 1                           | Model 2                           | Model 3                           |
| Resolution of NAFLD  |              |              |                                      |                                  |                                  |                                  |
| Inactive             | 17,358.3     | 1,181        | 6.8                                  | 1.00                             | 1.00                              | 1.00                              |
| Active               | 13,624.5     | 897          | 6.6                                  | 1.05 (0.97-1.15)                  | 1.10 (1.01-1.20)                  | 1.06 (0.97-1.16)                  |
| HEPA                 | 4,504.8      | 361          | 8.0                                  | 1.23 (1.09-1.38)                  | 1.33 (1.19-1.50)                  | 1.31 (1.16-1.47)                  |
|                      |              |              |                                      | Model 1                           | Model 2                           | Model 3                           |
| Incident NAFLD       |              |              |                                      |                                  |                                  |                                  |
| Inactive             | 39,646.9     | 1,100        | 2.8                                  | 1.00                             | 1.00                              | 1.00                              |
| Active               | 27,526.6     | 935          | 3.4                                  | 0.99 (0.91-1.08)                  | 0.97 (0.89-1.06)                  | 0.99 (0.91-1.09)                  |
| HEPA                 | 12,035.9     | 377          | 3.1                                  | 0.86 (0.76-0.96)                  | 0.85 (0.76-0.96)                  | 0.88 (0.78-0.99)                  |

Model 1: adjustment for age, sex, center, year of screening exam, smoking status, alcohol intake, education level

Model 2: model 1 adjustments plus adjustment for waist circumference

Model 3: model 2 adjustments plus adjustment for waist circumference changes

The reference group was inactive group.

Abbreviations: BMI, body mass index; CI, confidence interval; HEPA, health-enhancing physical activity; HR, hazard ratio; NAFLD, non-alcoholic fatty liver disease; PA, physical activity.

We divided the study participants into three groups to examine if there was a difference in the influence on the resolution or development of NAFLD according to their initial BMI: underweight (BMI<18.5), normal (BMI 18.5-23), and overweight (BMI>23) (Supporting Table S2). For the risk of incident NAFLD, overweight individuals showed greatest benefit with active PA or HEPA in both BMI change groups. In decreasing BMI group, overweight NAFLD individuals showed greatest benefits in resolution of NAFLD with active PA or HEPA. NAFLD individuals with normal BMI benefits with active PA or HEPA even in case of increasing BMI during follow-up.
TEMPORAL CHANGES IN PA AND NAFLD WITH TEMPORAL CHANGES IN BMI

We found an association of temporal changes in PA with the resolution and development of NAFLD in participants with temporal BMI changes (Tables 5 and 6). PA maintenance or enhancement was associated with a lower risk of incident NAFLD despite an increase in BMI (Table 5; HR 0.90 [0.85-0.96] for the inactive to active/HEPA group and HR 0.89 [0.85-0.93] for the active/HEPA to active/HEPA group); however, PA maintenance or enhancement was not associated with the resolution of NAFLD if the BMI increased (HR 1.16 [0.99-1.36] for the inactive to active/HEPA group and HR 1.10 [0.96-1.27] for the active/HEPA to active/HEPA group). Among participants with decreased BMI (Table 6), those with persistent active PA or HEPA showed increased resolution of NAFLD (HR 1.18 [1.07-1.31]). In this subset, the HR for incidence of NAFLD was 0.99 (0.89-1.12) for the PA enhancement category and 0.93 (0.83-1.03) for the PA maintenance category.
### Table 5

**HR of Resolution and Incident NAFLD According to Temporal PA Change in BMI Change >0 Group**

| Resolution of NAFLD | Person-years | Events (No.) | Event rate (per 100,000 person-years) | Age- and sex-adjusted HR (95% CI) | Multivariable-adjusted HR (95% CI) |
|---------------------|--------------|--------------|---------------------------------------|-----------------------------------|-----------------------------------|
| Inactive→Inactive   | 18,027.0     | 407          | 2.25                                  | 1.00                              | 1.04 (0.89-1.22) 1.04 (0.89-1.21) 1.07 (0.91-1.25) |
| Active or HEPA→Inactive | 12,962.8    | 268          | 2.06                                  | 0.98 (0.84-1.15)                  | 1.17 (0.99-1.37) 1.17 (0.99-1.37) 1.19 (1.02-1.40) 1.16 (0.99-1.36) |
| Inactive→Active or HEPA | 9,545.3    | 237          | 2.48                                  | 1.17 (0.99-1.37)                  | 1.08 (0.94-1.24) 1.12 (0.98-1.29) 1.11 (0.97-1.28) 1.10 (0.96-1.27) |
| Active or HEPA→Active or HEPA | 19,751.9  | 424          | 2.14                                  | 1.08 (0.94-1.24)                  | 1.05 (0.98-1.12) 1.04 (0.98-1.12) 1.03 (0.95-1.12) 1.02 (0.94-1.12) |
| Incident NAFLD      |              |              |                                       |                                   |                                   |
| Inactive→Inactive   | 63,556.4     | 3,448        | 5.45                                  | 0.99 (0.94-1.05)                  | 0.90 (0.85-0.96) 0.91 (0.86-0.96) 0.89 (0.84-0.94) 0.90 (0.85-0.96) |
| Active or HEPA→Inactive | 40,517.9    | 2,617        | 6.45                                  | 0.99 (0.94-1.05)                  | 0.90 (0.85-0.96) 0.91 (0.86-0.96) 0.89 (0.84-0.94) 0.90 (0.85-0.96) |
| Inactive→Active or HEPA | 30,474.9    | 1,768        | 5.80                                  | 0.90 (0.85-0.96)                  | 0.87 (0.83-0.92) 0.90 (0.86-0.94) 0.89 (0.85-0.94) 0.89 (0.85-0.93) |
| Active or HEPA→Active or HEPA | 59,022.7  | 3,821        | 6.47                                  | 0.87 (0.83-0.92)                  | 0.87 (0.83-0.92) 0.87 (0.83-0.92) 0.87 (0.83-0.92) 0.87 (0.83-0.92) |

- **Model 1**: adjustment for age, sex, center, year of screening exam, smoking status, alcohol intake, education level
- **Model 2**: model 1 adjustments plus adjustment for waist circumference
- **Model 3**: model 2 adjustments plus adjustment for waist circumference changes

The reference group was persistently inactive group.

Abbreviations: BMI, body mass index; CI, confidence interval; HEPA, health-enhancing physical activity; HR, hazard ratio; NAFLD, non-alcoholic fatty liver disease; PA, physical activity.
### Table 6
HR of Resolution and Incident NAFLD According to Temporal PA Change in BMI Change ≤0 Group

| Resolution of NAFLD | Person-years | Events (No.) | Event rate (per 100,000 person-years) | Age- and sex-adjusted HR (95% CI) | Multivariable-adjusted HR (95% CI) |
|---------------------|--------------|--------------|---------------------------------------|----------------------------------|-----------------------------------|
|                     |              |              |                                       | Model 1                          | Model 2                           | Model 3                           |
|                     |              |              |                                       | Model 1                          | Model 2                           | Model 3                           |
|                     |              |              |                                       | Model 1                          | Model 2                           | Model 3                           |
|                     |              |              |                                       | Model 1                          | Model 2                           | Model 3                           |
| Resolution of NAFLD |              |              |                                       | Model 1                          | Model 2                           | Model 3                           |
| Inactive→Inactive   | 9,984.5      | 679          | 6.80                                  | 0.97 (0.86-1.10)                 | 1.04 (0.92-1.18)                 | 1.01 (0.89-1.15)                 |
| Active or HEPA→Inactive | 6,053.5   | 381          | 6.29                                  | 1.04 (0.92-1.18)                 | 1.04 (0.92-1.18)                 | 1.04 (0.92-1.18)                 |
| Inactive→Active or HEPA | 7,373.8   | 502          | 6.80                                  | 1.05 (0.94-1.18)                 | 1.05 (0.94-1.18)                 | 1.08 (0.97-1.22)                 |
| Active or HEPA→Active or HEPA | 12,075.7 | 877          | 7.26                                  | 1.21 (1.09-1.34)                 | 1.26 (1.14-1.40)                 | 1.24 (1.12-1.38)                 |
| Incident NAFLD      |              |              |                                       | Model 1                          | Model 2                           | Model 3                           |
| Inactive→Inactive   | 25,070.9     | 650          | 2.59                                  | 1.04 (0.92-1.17)                 | 1.02 (0.91-1.15)                 | 1.02 (0.90-1.15)                 |
| Active or HEPA→Inactive | 14,209.1 | 452          | 3.18                                  | 1.04 (0.92-1.17)                 | 1.02 (0.91-1.15)                 | 1.00 (0.89-1.13)                 |
| Inactive→Active or HEPA | 14,575.9 | 450          | 3.08                                  | 1.03 (0.91-1.16)                 | 1.03 (0.91-1.16)                 | 0.94 (0.83-1.06)                 |
| Active or HEPA→Active or HEPA | 25,353.3 | 860          | 3.39                                  | 0.92 (0.83-1.02)                 | 0.90 (0.82-1.00)                 | 0.89 (0.80-0.99)                 |

Model 1: adjustment for age, sex, center, year of screening exam, smoking status, alcohol intake, education level

Model 2: model 1 adjustments plus adjustment for waist circumference

Model 3: model 2 adjustments plus adjustment for waist circumference changes

The reference group was persistently inactive group.

Abbreviations: BMI, body mass index; CI, confidence interval; HEPA, health-enhancing physical activity; HR, hazard ratio; NAFLD, non-alcoholic fatty liver disease; PA, physical activity.

### Discussion
This large longitudinal study identified several insightful findings. First, HEPA prevented incident NAFLD regardless of BMI changes. Second, HEPA is also related to the resolution of existing NAFLD when combined with BMI reduction. Third, PA maintenance or enhancement over the 3-yr follow-up period was related to the resolution of NAFLD and a decreased risk of incident NAFLD. These findings suggest that increasing PA could be an effective strategy to prevent or resolve NAFLD even in the absence of BMI reduction.

The current NAFLD management includes dietary and PA modifications mainly aimed at weight loss. Previous studies reported that exercise which did not induce weight loss can improve hepatic steatosis. Another study involving both obese and lean adolescents showed that a 12-wk aerobic exercise program reduced hepatic fat accumulation and insulin resistance in the absence of weight loss. Even in the absence of weight reduction, short-term aerobic exercise training reduced the hepatic lipid content, as assessed using magnetic resonance imaging and proton magnetic resonance spectroscopy (1H-MRS). A small randomized trial demonstrated that resistance exercise also reduced hepatic fat, increased insulin sensitivity, and improved metabolic flexibility in participants with NAFLD, independent of weight loss. These studies suggest that reduction in liver fat content is possible with exercise even in the absence of a considerable change in body weight.

In our longitudinal cohort study, a higher level of PA at baseline was associated with an increase in NAFLD resolution and a decrease in subsequent NAFLD development, even after adjustment for visceral obesity (waist circumference). The impact of increased PA was more pronounced when combined with BMI reduction. Despite worse baseline metabolic risk profiles than those with inactive PA, the HEPA group had a reduced incidence of NAFLD. This further emphasizes the importance of PA which might overcome worse metabolic risk profiles. The analysis according to the baseline BMI subgroups suggests that the overweight individual can benefit more from active PA or HEPA (Supporting Table S2). Systematic review showed that exercise only interventions without weight loss produce a modest but significant effect upon liver lipid (1H-MRS measured intrahepatic triacylglycerol concentration (IHTAG) of 1.8%, relative reduction of 21%) and lifestyle interventions producing weight loss significantly improve liver lipid (absolute reductions in IHTAG of 2%-4.6%, relative reductions of 13%-51%). These results could be interpreted that PA has beneficial effects regardless of weight changes, but the beneficial effects are more pronounced when weight loss is achieved, especially for the resolution of existing NAFLD. Abolition of the benefits of PA by weight gain may be a direct effect of weight gain itself or may be explained by the pathologic processes that cause increased body weight; however, the exact mechanisms warrant further studies. Since the prevalence or incidence of NAFLD in the underweight group was very low (Supporting Table S2), it is difficult to draw a clear conclusion on these cases (whether weight gain or loss has association with NAFLD in underweight NAFLD individuals), and further studies are needed in these population. Our findings emphasize the importance of PA in the resolution and prevention of NAFLD, as well as the greater benefits could be achieved when combined with a decrease in BMI. Furthermore, the amount of PA was associated with the resolution or prevention of NAFLD in a dose-dependent manner.
Our findings are also in accordance with the current guidelines for increasing PA and adopting long-term lifestyle changes. (17)

With respect to temporal changes in PA, our study showed that increasing the amount of PA to an active status or maintaining an active PA or HEPA status during the median follow-up of 3 yr was associated with NAFLD resolution or prevention. Compared with the persistently inactive group, active PA or HEPA at follow-up demonstrated a higher benefit on NAFLD resolution than baseline PA level. A cross-sectional study conducted in Korea showed that an increasingly sedentary lifestyle was associated with a high prevalence of NAFLD and that the risk of developing NAFLD decreased by 6% in the minimally active group compared with the inactive group. (18) Given the paucity of evidence, our results suggest that even a relatively short period of PA enhancement may provide a benefit to individuals with NAFLD. PA is thought to improve fatty liver through a variety of mechanisms. In previous studies, PA have been shown to reduce hepatic fat content through improvements in insulin resistance, (19) liver fatty acid metabolism, (20) liver mitochondrial function, and activation of inflammatory cascades. (21)

Our study had some limitations. An important limitation of this study was that the onset of new NAFLD and changes in PA levels could not be identified. Additional large-scale prospective studies are required to overcome this limitation. Present study used self-reported PA questionnaire which may be inaccurate. However, the IPAQ-SF is a widely used questionnaire in research that can determine the amount and frequency of PA relatively accurately. We diagnosed NAFLD using abdominal US. Liver biopsy is the gold standard method for the quantitative diagnosis of NAFLD. Nevertheless, US is currently the preferred method for the initial screening of NAFLD. Moreover, the sensitivity and specificity of US in diagnosing moderate to severe steatosis are rather high (78.4%-90.8% and 76.0%-90.0%, respectively). (22) Despite the limitations, the novelty of the study design and the large number of included participants are the strengths of our study.

**Conclusion**

In this large longitudinal study, PA was found to be associated with the prevention of NAFLD regardless of BMI changes. PA can result in the resolution of existing NAFLD particularly when combined with BMI reduction. Maintenance or enhancement of PA even for a short period can provide benefits in terms of NAFLD prevention or resolution.

**Abbreviations**

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DBP, diastolic blood pressure; GGT, gamma-glutamyl transferase; HEPA, health-enhancing physical activity; HOMA-IR, homeostatic model assessment of insulin resistance; HR, hazard ratio; IPAQ-SF, International Physical Activity Questionnaire Short Form; MET, metabolic equivalents; NAFLD, nonalcoholic fatty liver disease; PA, physical activity; SBP, systolic blood pressure; US, ultrasonography.
Declarations

**Ethics approval and consent to participate:** The Kangbuk Samsung Hospital Institutional Review Board approved this study and waived the requirement for informed consent because we used only de-identified data obtained as part of the health screening examinations (IRB No. 2018-05-050). All procedures performed in studies involving human participants were in accordance with the ethical standards of the national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**Consent for publication:** Not applicable

**Availability of data and materials:** Data are available upon request from the corresponding author due to institutional data protection. Research results must be reviewed through the corresponding author according to the guidelines for research results management of Korea Centers for Disease Control and Prevention. The interested researchers may contact to the corresponding author, Dr. Jong-Young Lee, e-mail address: jyleeheart@naver.com. Although the data are not available to be shared publicly, data are provided directly from the corresponding author to the individual researchers.

**Competing interests:** The authors declare that they have no competing interests.

**Funding:** Not applicable.

Author's contributions:

Hyo-In Choi- Formal Analysis, Investigation, Data Curation, Writing: Original Draft

Jong-Young Lee- Conceptualization, Methodology, Formal analysis, Writing: Original Draft, review and editing, Supervision.

Ki-Chul Sung- Conceptualization, Methodology, Formal analysis, Writing: Original Draft, review and editing, Supervision.

Mi Yeon Lee- Formal Analysis, Review and Editing

Hyunah Kim - Investigation, Writing: Review and Editing

Byeong Kil Oh - Investigation, Writing: Review and Editing

Seung Jae Lee - Investigation, Writing: Review and Editing

Jeong Gyu Kang – Data collection, Writing: Review and Editing

Sung Ho Lee - Investigation, Writing: Review and Editing

Byung Jin Kim - Conceptualization, Writing: Review and Editing
Acknowledgements: Not applicable.

References

1. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313:2263–2273.
2. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–285.
3. Dulai PS, Singh S, Patel J et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017;65:1557–1565.
4. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65:589–600.
5. Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–357.
6. Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol. 2011;106:460–468; quiz 469.
7. Church TS, Kuk JL, Ross R, Priest EL, Biltoft E, Blair SN. Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology. 2006;130:2023–2030.
8. Sung KC, Ryu S, Lee JY, Kim JY, Wild SH, Byrne CD. Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver. J Hepatol. 2016;65:791–797.
9. Chun MY. Validity and reliability of korean version of international physical activity questionnaire short form in the elderly. Korean J Fam Med. 2012;33:144–151.
10. Fogelholm M, Malmberg J, Suni J et al. International Physical Activity Questionnaire: Validity against fitness. Med Sci Sports Exerc. 2006;38:753–760.
11. Hernaez R, Lazo M, Bonekamp S et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54:1082–1090.
12. Johnson NA, Sachinwalla T, Walton DW et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology. 2009;50:1105–1112.
13. van der Heijden GJ, Wang ZJ, Chu ZD et al. A 12-week aerobic exercise program reduces hepatic fat accumulation and insulin resistance in obese, Hispanic adolescents. Obesity (Silver Spring). 2010;18:384–390.
14. Shojaee-Moradie F, Baynes KC, Pentecost C et al. Exercise training reduces fatty acid availability and improves the insulin sensitivity of glucose metabolism. *Diabetologia*. 2007;50:404–413.

15. Hallsworth K, Fattakhova G, Hollingsworth KG et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. *Gut*. 2011;60:1278–1283.

16. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. *J Hepatol*. 2012;56:255–266.

17. Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology*. 2012;55:2005–2023.

18. Ryu S, Chang Y, Jung HS et al. Relationship of sitting time and physical activity with non-alcoholic fatty liver disease. *J Hepatol*. 2015;63:1229–1237.

19. Winn NC, Liu Y, Rector RS, Parks EJ, Ibdah JA, Kanaley JA. Energy-matched moderate and high intensity exercise training improves nonalcoholic fatty liver disease risk independent of changes in body mass or abdominal adiposity - A randomized trial. *Metabolism*. 2018;78:128–140.

20. Golabi P, Locklear CT, Austin P et al. Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review. *World J Gastroenterol*. 2016;22:6318–6327.

21. Stevanović J, Beleza J, Coxito P, Ascensão A, Magalhães J. Physical exercise and liver "fitness": Role of mitochondrial function and epigenetics-related mechanisms in non-alcoholic fatty liver disease. *Mol Metab*. 2020;32:1–14.

22. Bohte AE, van Werven JR, Bipat S, Stoker J. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. *Eur Radiol*. 2011;21:87–97.

**Figures**
Figure 1

Kaplan-Meier (KM) curves according to physical activity (PA) categories for the resolution and incident development of nonalcoholic fatty liver disease (NAFLD) in different body mass index (BMI) change groups. (A) KM curves for NAFLD resolution in the BMI change >0 group. (B) KM curves for incident NAFLD development in the BMI change >0 group. (C) KM curves for NAFLD resolution in the BMI change ≤0 group. (D) KM curves for incident NAFLD development in the BMI change ≤0 group.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupportingFig1.tif
- Supplementarytables.docx
- Supportingfigurelegend.docx